New drug approvals all but screeched to a halt in 2016, with a measly 22 new OKs after a pair of bountiful years. But the FDA wasted no time in 2017, signing off on 12 drugs in the first quarter alone—besting its record for the same period of any year in recent history.
MetaLinear is a start-up biotechnology company founded in 2017, focused on the identification and validation of new drug targets for difficult to treat bacterial infections. The new investment was secured from the BioCity Group Ltd, who manage the Alderley Park Ventures (APV) fund and Catapult Ventures, who manage the Greater Manchester and Cheshire (GM&C) Life Sciences Fund. Both funds look to back innovative, high-technology companies providing much needed early stage finance.
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.